FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 03/2021”.
The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of March 2021, we identify the following current VC trends in the US-Biotech sector:
- In 2021, overall Biotech funding in the USA has reached USD 8,953m so far
- Top 5 deals exceed USD 200m each, largest transaction amounted to USD 525m in EQRx, Inc.
- Logos Capital (USA) still leads the Top 5 Investors (by deal volume), Cormorant Asset Management (USA) took over second rank followed by HBM Partners (Switzerland)
- Oncology still dominates as the top indication
To access the full report, please click here.